A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice.

Prophylactic oral administration of a novel immunomodulator (immunosuppressant), FTY720 (1 mg/kg, three times a week), completely prevented the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL/6 mice. EAMG has been used as an animal model for human myasthenia gravis, and was established by immunizing the mice with acetylcholine receptor (AChR) from Torpedo californica. FTY720 also suppressed the production of both anti-Torpedo californica AChR antibody and anti-mouse AChR autoantibody by the mice, which were observed in mice in which EAMG had become established. These results strongly suggest that FTY720 is a promising candidate for treatment of human myasthenia gravis.

[1]  K. Watabe,et al.  A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. , 2004, Biological & pharmaceutical bulletin.

[2]  E. Mukai,et al.  Clinical study of fk506 in patients with myasthenia gravis , 2003, Muscle & nerve.

[3]  S. Mulgaonkar,et al.  Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study , 2003, Transplantation.

[4]  K. Budde,et al.  Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. , 2003, International journal of clinical pharmacology and therapeutics.

[5]  M. Fukuzawa,et al.  The Effect of a Novel Immunosuppressant, FTY720, in Mice Without Secondary Lymphoid Organs , 2003, Surgery Today.

[6]  J. Nedelman,et al.  Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  K. Budde,et al.  FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. , 2002, Transplantation Proceedings.

[8]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[9]  K. Budde,et al.  First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.

[10]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[11]  T. Hanano,et al.  Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. , 2000, Journal of medicinal chemistry.

[12]  L. Feng,et al.  FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.

[13]  K. Sugahara,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. , 1998, Journal of immunology.

[14]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[15]  P. Karachunski,et al.  Nasal Administration of Synthetic Acetylcholine Receptor T Epitopes Affects the Immune Response to the Acetylcholine Receptor and Prevents Experimental Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.

[16]  P. Karachunski,et al.  Immunization of bm12 Mice with High Doses of Acetylcholine Receptor Overcomes Their Resistance to Experimental Autoimmune Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.

[17]  T. Fujita,et al.  Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .

[18]  T. Okumoto,et al.  Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. , 1994, The Journal of antibiotics.

[19]  E. Ishikawa,et al.  A more sensitive enzyme immunoassay of anti-insulin IgG in guinea pig serum with less non-specific binding of normal guinea pig IgG. , 1985, Journal of Biochemistry (Tokyo).

[20]  P. Berman,et al.  Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis , 1980, The Journal of experimental medicine.

[21]  P. Berman,et al.  Experimental myasthenia gravis. A murine system , 1980, The Journal of experimental medicine.

[22]  S. Froehner,et al.  Comparison of the subunits of Torpedo californica acetylcholine receptor by peptide mapping. , 1979, Biochemistry.

[23]  R. Almon,et al.  Acetylcholine receptor antibodies in myasthenia gravis. , 1975, The New England journal of medicine.

[24]  K. Watabe,et al.  Antibodies to food antigens in Japanese patients with type 1 diabetes mellitus. , 2002, Diabetes research and clinical practice.